Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
Authors:
Open Access
- 1 March 2011
- journal article
- Published by Taylor & Francis in Core Evidence
- Vol. 6, 31-42
Abstract
Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. Aims: To update the evidence and provide an overview of the available data on ticagrelor. Evidence review: Peer reviewed articles published and listed under Medline Search, and published updated guidelines for pharmacotherapies in acute coronary syndromes were reviewed. Place in therapy: Clinical evidence is increasing to support the use of new thienopyridines and the direct-acting P2Y12 receptor in the setting of acute coronary syndromes. Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.Keywords
This publication has 32 references indexed in Scilit:
- Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelorVascular Health and Risk Management, 2010
- The TRITON versus PLATO trials: Differences beyond platelet inhibitionThrombosis and Haemostasis, 2010
- Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?2009
- Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary SyndromeJACC, 2007
- ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionCirculation, 2007
- Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEuropean Heart Journal, 2006
- Pharmacokinetics of clopidogrel after administration of a high loading doseThrombosis and Haemostasis, 2004
- The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activityBritish Journal of Haematology, 2000
- Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.Circulation, 1990
- Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty.Circulation, 1988